• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    5/15/24 1:35:22 PM ET
    $BMRN
    $BSX
    $CVS
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BMRN alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    CVS CALL TRADE BEARISH 06/07/24 $56.00 $38.2K 765 2.1K
    BMRN CALL SWEEP BEARISH 09/20/24 $90.00 $27.8K 276 1.9K
    JAZZ PUT SWEEP BEARISH 06/21/24 $110.00 $37.3K 129 276
    NVCR CALL SWEEP NEUTRAL 09/20/24 $25.00 $25.3K 446 220
    BSX PUT SWEEP BULLISH 01/16/26 $62.50 $37.4K 206 138
    PFE CALL SWEEP BULLISH 08/16/24 $27.00 $26.9K 7.4K 128
    LLY PUT TRADE NEUTRAL 06/21/24 $780.00 $61.6K 382 115
    UNH CALL TRADE NEUTRAL 06/28/24 $520.00 $36.7K 15 114
    JNJ CALL TRADE BEARISH 06/07/24 $150.00 $30.0K 115 103
    MRK CALL TRADE BEARISH 05/17/24 $120.00 $56.7K 4.4K 62

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • Regarding CVS (NYSE:CVS), we observe a call option trade with bearish sentiment. It expires in 23 day(s) on June 7, 2024. Parties traded 330 contract(s) at a $56.00 strike. The total cost received by the writing party (or parties) was $38.2K, with a price of $116.0 per contract. There were 765 open contracts at this strike prior to today, and today 2101 contract(s) were bought and sold.

    • Regarding BMRN (NASDAQ:BMRN), we observe a call option sweep with bearish sentiment. It expires in 128 day(s) on September 20, 2024. Parties traded 105 contract(s) at a $90.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $265.0 per contract. There were 276 open contracts at this strike prior to today, and today 1969 contract(s) were bought and sold.

    • For JAZZ (NASDAQ:JAZZ), we notice a put option sweep that happens to be bearish, expiring in 37 day(s) on June 21, 2024. This event was a transfer of 89 contract(s) at a $110.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $37.3K, with a price of $420.0 per contract. There were 129 open contracts at this strike prior to today, and today 276 contract(s) were bought and sold.

    • Regarding NVCR (NASDAQ:NVCR), we observe a call option sweep with neutral sentiment. It expires in 128 day(s) on September 20, 2024. Parties traded 110 contract(s) at a $25.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $25.3K, with a price of $230.0 per contract. There were 446 open contracts at this strike prior to today, and today 220 contract(s) were bought and sold.

    • For BSX (NYSE:BSX), we notice a put option sweep that happens to be bullish, expiring in 611 day(s) on January 16, 2026. This event was a transfer of 129 contract(s) at a $62.50 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $37.4K, with a price of $290.0 per contract. There were 206 open contracts at this strike prior to today, and today 138 contract(s) were bought and sold.

    • Regarding PFE (NYSE:PFE), we observe a call option sweep with bullish sentiment. It expires in 93 day(s) on August 16, 2024. Parties traded 100 contract(s) at a $27.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.9K, with a price of $266.0 per contract. There were 7459 open contracts at this strike prior to today, and today 128 contract(s) were bought and sold.

    • For LLY (NYSE:LLY), we notice a put option trade that happens to be neutral, expiring in 37 day(s) on June 21, 2024. This event was a transfer of 29 contract(s) at a $780.00 strike. The total cost received by the writing party (or parties) was $61.6K, with a price of $2125.0 per contract. There were 382 open contracts at this strike prior to today, and today 115 contract(s) were bought and sold.

    • For UNH (NYSE:UNH), we notice a call option trade that happens to be neutral, expiring in 44 day(s) on June 28, 2024. This event was a transfer of 30 contract(s) at a $520.00 strike. The total cost received by the writing party (or parties) was $36.7K, with a price of $1224.0 per contract. There were 15 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold.

    • For JNJ (NYSE:JNJ), we notice a call option trade that happens to be bearish, expiring in 23 day(s) on June 7, 2024. This event was a transfer of 100 contract(s) at a $150.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $300.0 per contract. There were 115 open contracts at this strike prior to today, and today 103 contract(s) were bought and sold.

    • For MRK (NYSE:MRK), we notice a call option trade that happens to be bearish, expiring in 2 day(s) on May 17, 2024. This event was a transfer of 50 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $56.7K, with a price of $1135.0 per contract. There were 4433 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BMRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRN
    $BSX
    $CVS
    $JAZZ

    CompanyDatePrice TargetRatingAnalyst
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    Pfizer Inc.
    $PFE
    3/2/2026$35.00Hold → Buy
    Argus
    Jazz Pharmaceuticals plc
    $JAZZ
    2/27/2026$224.00Overweight
    Barclays
    Pfizer Inc.
    $PFE
    2/25/2026$25.00Underperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    More analyst ratings

    $BMRN
    $BSX
    $CVS
    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

    Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancerRARITAN, N.J., March 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (FGFR) alterations. The study met its pri

    3/13/26 12:35:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

    New results demonstrate early VOXZOGO treatment leads to durable and sustained improvements in skeletal growth-related health outcomes, including proportionality, arm span and body mass index, building on over 10,000 patient-years of data  VOXZOGO is the only approved treatment for children with achondroplasia starting at birth and has the most extensive published clinical evidence, including in measures beyond growth, among all achondroplasia treatmentsSAN RAFAEL, Calif., March 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced positive new data from studies of VOXZOGO® (vosoritide) in children with achondroplasia in ongoing clinical trials and real-world st

    3/12/26 9:05:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

    97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL1 97% of patients would recommend this IOL to friends or family2 TECNIS PureSee IOL is the first and only U.S. FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL1* Johnson & Johnson (NYSE:JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery.1 TECNIS PureSee IOL delivers clarity of vision for patients, with 97% of them reporting no very bothersome visual disturbances.1 TECNIS Pure

    3/12/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    3/12/26 9:31:29 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pinto Daniel E

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    3/12/26 8:39:41 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    3/12/26 8:37:30 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Pfizer upgraded by Argus with a new price target

    Argus upgraded Pfizer from Hold to Buy and set a new price target of $35.00

    3/2/26 8:00:47 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Jazz Pharma with a new price target

    Barclays initiated coverage of Jazz Pharma with a rating of Overweight and set a new price target of $224.00

    2/27/26 8:31:30 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    SEC Filings

    View All

    SEC Form DEFA14A filed by Pfizer Inc.

    DEFA14A - PFIZER INC (0000078003) (Filer)

    3/12/26 9:12:24 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Pfizer Inc.

    DEF 14A - PFIZER INC (0000078003) (Filer)

    3/12/26 9:05:18 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Johnson & Johnson

    DEFA14A - JOHNSON & JOHNSON (0000200406) (Filer)

    3/11/26 6:17:23 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Chief Executive Officer Cordova Ashley bought $996,859 worth of Ordinary Shares (81,550 units at $12.22), increasing direct ownership by 23% to 437,569 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    9/8/25 7:10:52 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    Leadership Updates

    Live Leadership Updates

    View All

    ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

    Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (NASDAQ:PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel ((a subsidiary of Pfizer Inc., NYSE:PFE). In that

    3/4/26 8:32:00 AM ET
    $PFE
    $PRZO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Military/Government/Technical
    Industrials

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    Financials

    Live finance-specific insights

    View All

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of

    3/2/26 4:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

    Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally advanced pancreatic cancer, commercial launch underway Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "In 2025, a record number of patients received treatment with Novocure's Tumor Treating Fields therapy, a milestone that reflects our growth and commitment to advanc

    2/26/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $BMRN
    $BSX
    $CVS
    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BioMarin Pharmaceutical Inc.

    SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    9/30/24 4:29:01 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care